Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Associazione Italiana Ematologia Oncologia Pediatrica |
---|---|
Information provided by: | Associazione Italiana Ematologia Oncologia Pediatrica |
ClinicalTrials.gov Identifier: | NCT00613457 |
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: Thisphase III trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Drug: dexamethasone Drug: asparaginase Drug: Asparaginase Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin Drug: doxorubicin Drug: Etoposide Drug: Ifosfamide Drug: mercaptopurine Drug: Methotrexate Drug: prednisone Drug: thioguanine Drug: Vincristine Drug: Vindesine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study |
Official Title: | AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia |
Enrollment: | 2039 |
Study Start Date: | September 2000 |
Study Completion Date: | July 2006 |
Primary Completion Date: | July 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
I: No Intervention
|
Drug: asparaginase
native E-coli Asparaginase 5,000 IU/sqm x 8 doses
Drug: cyclophosphamide
1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
Drug: cytarabine
75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
Drug: daunorubicin
30 mg/sqm i.v. 4 doses in Induction phase
Drug: mercaptopurine
60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Drug: Methotrexate
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Drug: prednisone
60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
Drug: Vincristine
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
|
II: Experimental
|
Drug: dexamethasone
10 mg/sqm/day from for 21 days
Drug: asparaginase
native E-coli Asparaginase 5,000 IU/sqm x 8 doses
Drug: cyclophosphamide
1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
Drug: cytarabine
75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
Drug: daunorubicin
30 mg/sqm i.v. 4 doses in Induction phase
Drug: mercaptopurine
60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Drug: Methotrexate
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Drug: Vincristine
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
|
Reintensification Arm I: No Intervention
|
Drug: Asparaginase
native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
Drug: cyclophosphamide
1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
Drug: cytarabine
75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
Drug: doxorubicin
30 mg/sqm i.v. x 4 doses in Protocol II and III
Drug: mercaptopurine
60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Drug: Methotrexate
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Drug: thioguanine
60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
Drug: Vincristine
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
|
Reintensification Arm II: Experimental
|
Drug: Asparaginase
native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
Drug: cyclophosphamide
1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
Drug: cytarabine
75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
Drug: doxorubicin
30 mg/sqm i.v. x 4 doses in Protocol II and III
Drug: mercaptopurine
60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Drug: Methotrexate
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Drug: thioguanine
60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
Drug: Vincristine
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
|
Reintensification Arm III: Experimental
|
Drug: Asparaginase
native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
Drug: cytarabine
75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
Drug: doxorubicin
30 mg/sqm i.v. x 4 doses in Protocol II and III
Drug: mercaptopurine
60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Drug: Methotrexate
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Drug: Vincristine
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
|
Reintensification Arm IV: No Intervention
Patients then proceed to maintenance therapy.
|
Drug: Etoposide
100 mg/sqm i.v. for 3 doses in HR block 3
Drug: Ifosfamide
800 mg/sqm i.v.q12h x 5 in HR block 2
Drug: Methotrexate
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Drug: Vincristine
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
Drug: Vindesine
3 mg/sqm i.v. x 2 doses in HR block 2
|
Reintensification Arm V: Experimental
|
Drug: Etoposide
100 mg/sqm i.v. for 3 doses in HR block 3
Drug: Ifosfamide
800 mg/sqm i.v.q12h x 5 in HR block 2
Drug: Methotrexate
by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Drug: Vincristine
1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
Drug: Vindesine
3 mg/sqm i.v. x 2 doses in HR block 2
|
Ages Eligible for Study: | 1 Year to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Clinica Pediatrica Università di MIlano Bicocca ( Giuseppe Masera MD ) |
Study ID Numbers: | AIEOP LLA 2000, AIEOP LLA 2000 |
Study First Received: | January 21, 2008 |
Last Updated: | February 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00613457 History of Changes |
Health Authority: | ITALY:Agenzia Italiana del Farmaco (AIFA) |
Anti-Inflammatory Agents Antimetabolites Acute Lymphoblastic Leukemia, Childhood Dexamethasone Daunorubicin Prednisone Leukemia, Lymphoid Immunologic Factors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Vindesine Antiemetics Cyclophosphamide 6-Mercaptopurine Hormones |
Etoposide phosphate Anti-Bacterial Agents Leukemia Methotrexate Alkylating Agents Lymphoma Etoposide Dexamethasone acetate Cytarabine Acute Lymphoblastic Leukemia Asparaginase Immunoproliferative Disorders Precursor Cell Lymphoblastic Leukemia-Lymphoma Antineoplastic Agents, Hormonal Thioguanine |
Dexamethasone Anti-Inflammatory Agents Prednisone Anti-Infective Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics 6-Mercaptopurine Hormones Therapeutic Uses Abortifacient Agents Methotrexate Dermatologic Agents |
Nucleic Acid Synthesis Inhibitors Asparaginase Precursor Cell Lymphoblastic Leukemia-Lymphoma Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents, Hormonal Thioguanine Vincristine Abortifacient Agents, Nonsteroidal Glucocorticoids Doxorubicin Neoplasms Antineoplastic Agents, Phytogenic Antimetabolites Daunorubicin |